home genetic news bioinformatics biotechnology literature journals ethics positions events sitemap

UBBFriend: Email This Page to Someone!
  Biotechnical requests and sources
  Discover the Next IDE Inhibitor with the Newly Launched SensoLyteŽ IDE Activity Assay

Post New Topic  Post A Reply
profile | register | preferences | faq | search

next newest topic | next oldest topic
Author Topic:   Discover the Next IDE Inhibitor with the Newly Launched SensoLyteŽ IDE Activity Assay
posted 06-11-2014 01:03 AM     Click Here to See the Profile for anaspec   Click Here to Email anaspec     Edit/Delete Message Reply w/Quote
Discover your next Insulin Degrading Enzyme (IDE) inhibitor by using the newly launched SensoLyteŽ 520 IDE activity assay from AnaSpec. This is the first FRET-based (Ex/Em=490/520 nm) IDE assay that is commercially available and can be used for high-throughput screening (HTS) of IDE inhibitor lead compounds. The highly sensitive substrate used in the assay can detect as low as 0.8 ng/ml active IDE and has minimal cross reaction with Neprilysin, TACE, -Secretase, ADAM10 and BACE2.
Insulin degrading enzyme (IDE), an extremely conserved Zn2+ metalloendopeptidase, belongs to the M16A metallopeptidase family (1-3). IDE is expressed in almost all tissues and distributed in the cytosol. It degrades various substrates such as insulin, IGF-II, TGF-α, glucagon, amylin, calcitonin, β-amyloid and amyloid precursor protein (APP) (4-6). Growing evidence has indicated that IDE may be involved in the pathogenesis of Alzheimer's disease and diabetes mellitus type 2 (2, 7, 8).

For more information, please visit: https://www.anaspec.com/products/promotions.asp?id=125&col=2&row=1

1. Fernández-Gamba, A. et al. Curr Pharm Des 15, 3644 (2009).
2. McCord, LA. et al. Proc Natl Acad Sci USA 110, 13827 (2013).
3. de Tullio, MB. et al. Prion 2, 51 (2008).
4. Edbauer, D. et al. J Biol Chem 277, 13389 (2002).
5. Morelli, L. et al. Biochem Biophys Res Commun 332, 808 (2005).
6. Kurochkin, IV. Trends Biochem Sci 26, 421 (2001).
7. Delledonne, A. et al. Mol Neurodegener 4, 39 (2009).
8. Zhao, J. et al. Mol Neurodegener 4, 4 (2009).

AnaSpec, EGT Group
AnaSpec, EGT Group is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and Takyon™ qPCR MasterMixes. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening (HTS) and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

For more information visit: www.anaspec.com


All times are ET (US)

next newest topic | next oldest topic

Administrative Options: Close Topic | Archive/Move | Delete Topic
Post New Topic  Post A Reply
Hop to:

Contact Us | HUM-MOLGEN

Copyright by HUM-MOLGEN 1995-2017

Powered by: Ultimate Bulletin Board, Version 5.44a
© Infopop Corporation (formerly Madrona Park, Inc.), 1998 - 2000.